Quick Answer
Ginkgo Bioworks Holdings, Inc. reported Operating Income Loss of -$315.28 million for the year ending 2025.
- Ginkgo Bioworks Holdings, Inc. showed an increase of +43.7% in Operating Income Loss from 2024 to 2025.
- This data is from Ginkgo Bioworks Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: -$34.41 million | Q1 2021: -$57.12 million | Q2 2021: -$59.95 million | Q3 2021: -$26.67 million | Q1 2022: -$675.37 million | Q2 2022: -$647.78 million | Q3 2022: -$654.94 million | Q1 2023: -$215.75 million | Q2 2023: -$184.15 million | Q3 2023: -$286.39 million | Q1 2024: -$178.00 million | Q2 2024: -$222.95 million | Q3 2024: -$55.20 million | Q1 2025: -$88.97 million | Q2 2025: -$65.54 million | Q3 2025: -$90.02 million.
- Over the full 7 years of available data (2019 to 2025), Ginkgo Bioworks Holdings, Inc.'s Operating Income Loss has declined by 340.3%.
- Historical annual values: Fiscal year 2025: -$315.28 million | Fiscal year 2024: -$559.76 million | Fiscal year 2023: -$864.41 million | Fiscal year 2022: -$2.21 billion | Fiscal year 2021: -$1.83 billion | Fiscal year 2020: -$137.03 million | Fiscal year 2019: -$71.60 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: